首页> 外文OA文献 >PCN100 Cost-Effectiveness Model of Pertuzumab in Combination with Trastuzumab and Docetaxel Compared with Trastuzumab in Combination with Docetaxel for the 1st Line Treatment of HER2+ Metastatic Breast Cancer in Colombia

【2h】

PCN100 Cost-Effectiveness Model of Pertuzumab in Combination with Trastuzumab and Docetaxel Compared with Trastuzumab in Combination with Docetaxel for the 1st Line Treatment of HER2+ Metastatic Breast Cancer in Colombia

机译：帕妥珠单抗联合曲妥珠单抗和多西他赛联合治疗的PCN100成本-效果模型与曲妥珠单抗联合多西他赛联合用于哥伦比亚HER2 +转移性乳腺癌的一线治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Saenz Ariza S.A.;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. [J] . Hamberg P, Bos MM, Braun HJ, Clinical breast cancer . 2011,第2期

机译：II期随机研究比较了曲妥珠单抗和多西他赛联合治疗与序贯治疗的曲妥珠单抗联合多西他赛在HER2 +转移性乳腺癌患者一线化疗中的疗效和安全性：HERTAX试验。
2. Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer [J] . Fleeman Nigel, Bagust Adrian, Beale Sophie, PharmacoEconomics . 2015,第1期

机译：帕妥珠单抗联合曲妥珠单抗和多西他赛治疗HER2阳性转移性或局部复发性不可切除乳腺癌
3. Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma [J] . van Boxtel Wim, Boon Eline, Weijs Willem L. J., Oral oncology . 2017,第期

机译：Docetaxel，Trastuzumab和Pertuzumab的组合或用曲妥珠单抗治疗用于转移性唾液管癌
4. Efficacy of combination chemotherapy with docetaxel and irinotecan as first- or second-line treatment for advanced gastric cancer [C] . K. Sugiyama, A. Ishikawa, T. Watanabe International Gastric Cancer Congress . 2009

机译：组合化疗与多西紫杉醇和伊替康的疗效，作为晚期胃癌的第一或二线治疗
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer [O] . Angelica L. Quartino, Hanbin Li, Jin Y. Jin, -1

机译：帕妥珠单抗联合曲妥珠单抗和多西紫杉醇在HER2 +早期乳腺癌新辅助治疗中的药代动力学和暴露-反应分析
7. Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer [O] . 2017

机译：帕妥珠单抗联合曲妥珠单抗和多西紫杉醇在HER2 +早期乳腺癌新辅助治疗中的药代动力学和暴露-反应分析

PCN100 Cost-Effectiveness Model of Pertuzumab in Combination with Trastuzumab and Docetaxel Compared with Trastuzumab in Combination with Docetaxel for the 1st Line Treatment of HER2+ Metastatic Breast Cancer in Colombia

著录项

相似文献

相关主题

期刊订阅